Page 2 - Booster Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate VALNEVAMarch 8, 2021 GMT The Phase 2 study will include both adult and pediatric subjects with an aim to support acceleration of the vaccine candidate’s pediatric program   VLA15 will be  tested at two different schedules (Month 0-2-6 or Month 0-6) receiving the selected dose of 180µg VLA15 is the only Lyme disease vaccine candidate in active clinical development Saint-Herblain (France) and New York, NY, ...

Valneva and Pfizer have initiated a Phase 2 study for their Lyme disease vaccine candidate: which is the only active Lyme disease vaccine in clinical development today.